Cytomegalovirus-based Cancer Immunotherapy
The emergence of various immunotherapies has brought hope and dawn to the treatment of cancer. Among the many immunotherapies, cytomegalovirus has become a blockbuster for cancer treatment because of its unique advantages. Creative Biolabs has made significant progress in cancer immunotherapy with its extensive experience in vaccine research, establishing a comprehensive system of research systems and launching a range of high-quality products and services that will allow you to develop cancer immunotherapy handier.
CMV: A New Method for Adoptive Immunotherapy
Cytomegalovirus (CMV) is a herpesvirus that usually causes asymptomatic latent infection and lasts for a lifetime. Infection caused by the virus in a latent state usually recurs regularly, so the host needs to maintain immune surveillance of the virus to ensure the health of the body. Past studies have found that CMV nucleic acids and proteins are present in human glioblastoma (GBM), breast, rhabdomyosarcoma, and prostate cancer samples. Although the relationship between the virus and cell carcinogenesis is still unclear, scientists have used CMV as a target for the treatment of malignant glioma based on the fact that the virus is present in the above cancer tissues. Clinical trials have shown that the use of anti-CMV drugs based on standard therapies can significantly improve the survival rate of GBM patients. Therefore, some clinical trials that use CMV-specific T cells, or dendritic cells which were pulsed with CMV pp65 RNA, have been undergoing. Results show that these T cells can infiltrate GBM cancer tissues and DCs treated with CMV RNA can stimulate the production of T cells killing GBM. In addition, under in vitro operating conditions, the function of T cells can be repaired by stimulation of cytokines. To some extent, in vitro expansion and inoculation of T cells may enhance the ability of CMV-specific T cells to kill infected cancerous tissues.
CMV as A Vaccine Platform for Cancer Treatment
CMV can produce a strong inflammatory natural immune response after infection in humans, causing the expansion of robust CD8+ T cells. At the same time, CMV-specific CD8+ T cells can be permanently expanded in the host. This process that continues for the whole life of the infected people is called T cell inflation. Even more gratifying is that unlike other viruses, CMV can repeatedly infect individuals who have already been infected with this virus, which enables CMV-seropositive people to also be vaccinated with CMV-vectored vaccine. Moreover, the stable double-stranded DNA genome of CMV enables it to express a variety of foreign genes, making it an ideal vector for the expression of multiple tumor antigens. The results of mouse and non-human primate experiments show that recombinant CMV can stimulate memory T cell expansion against the antigen of interest in these animals. It is worth noting that recombinant murine cytomegalovirus (MCMV) has shown some preventive and therapeutic effects in cancer models such as melanoma and prostate cancer. There are also some data showing that CMV-induced γδ-T cells and NK cells may be able to fight tumors.
Fig.1 Maintenance of numbers of cytomegalovirus-specific T cells during persistent/latent infection in a healthy host. (Quinn M and Erkes DA, 2016)
Our Services for Cytomegalovirus-based Immunotherapy
- Prediction of tumor-specific neoantigen
- Design and preparation of CMV-vectored vaccine
- Evaluation of CMV-vectored vaccine
- CMV-induced expansion and infusion of T cells
- Assessment of CMV-based adoptive immunotherapy
Cytomegalovirus-based immunotherapy has shown great potential in cancer treatment. Creative Biolabs' s keen sense of possible cancer therapy and the creative combination of various immunotherapies have yielded promising results in cancer treatment. Our experience and proven services in this area can help all cancer researchers complete their research with greater efficiency.
Reference
- Quinn M, Erkes DA. (2016). “Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector”. Immunotherapy. 8(2):211-21
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
